Xceleron sign an agreement with Biofrontera Bioscience GmbH to accelerate drug development using microdosing
Dr Reinhold Gahlmann, Managing Director of Biofrontera Bioscience GmbH, commented: "Our collaboration with Xceleron, and the use of their highly innovative approach, will save Biofrontera significant time and cost, allowing us to focus resources on our most promising preclinical drug candidates going forward".
Xceleron will co-ordinate the complete microdose project from synthesis through clinical trials (with Dutch clinical partners Pharma Bio-research) and finally zeptoanalysis at the Company's GLP accredited laboratories in York, UK using ultra-sensitive accelerator mass spectrometery (AMS) - the world's most sensitive measuring device that enables the microdosing concept.
"This agreement means that Biofrontera becomes Xceleron's 89th client and confirms that microdosing is fast becoming an accepted approach in drug development with the interface between preclinical and clinical trial stages radically changing" said Professor Colin Garner, Xceleron's CEO.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.